HemOnc Today 

The U.S. Food and Drug Administration approved bevacizumab for use with chemotherapy, followed by bevacizumab as a single agent, for the treatment of women with advanced ovarian cancer who underwent initial surgical resection. Bevacizumab (Avastin, Genentech) is now approved for 10 indications in the United States. These include advanced cervical cancer and two forms of ovarian cancer that recurred after platinum-based chemotherapy.  

Read more.